Literature DB >> 22272656

Hepatitis C virus infection is associated with painful symptoms in HIV-infected adults.

Judith I Tsui1, Debbie M Cheng, Howard Libman, Carly Bridden, Jeffrey Samet.   

Abstract

The study aim was to assess whether hepatitis C virus (HCV) was associated with painful symptoms among patients with HIV. Using data from a prospective cohort of HIV-infected adults with alcohol problems, we assessed the effects of HCV on pain that interfered with daily living and painful symptoms (muscle/joint pain, headache and peripheral neuropathy). Exploratory analyses assessed whether depressive symptoms and inflammatory cytokines mediated the relationship between HCV and pain. HCV-infected participants (n = 200) had higher odds of pain that interfered with daily living over time (adjusted odds ratio [AOR] 1.43; 95% CI: 1.02-2.01; p = 0.04) compared to those not infected with HCV. HIV/HCV co-infected participants had higher odds of muscle or joint pain (AOR 1.45; 95% CI: 1.06-1.97; p = 0.02) and headache (AOR 1.57; 95% CI: 1.18-2.07; p<0.01). The association between HCV and peripheral neuropathy did not reach statistical significance (AOR 1.33; 95% CI: 0.96-1.85; p = 0.09). Depressive symptoms and inflammatory cytokines did not appear to mediate the relationship between HCV and pain. Adults with HIV who are also co-infected with HCV are more likely to experience pain that interfered with daily living, muscle or joint pain, and headaches compared to those not co-infected. Research is needed to explore the association between HCV infection and pain, and to determine whether HCV treatment is an effective intervention.

Entities:  

Mesh:

Year:  2012        PMID: 22272656      PMCID: PMC3370099          DOI: 10.1080/09540121.2011.642989

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  52 in total

1.  A comparison of pain report and adequacy of analgesic therapy in ambulatory AIDS patients with and without a history of substance abuse.

Authors:  W Breitbart; B Rosenfeld; S Passik; M Kaim; J Funesti-Esch; K Stein
Journal:  Pain       Date:  1997-08       Impact factor: 6.961

Review 2.  Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies.

Authors:  Jennifer M Loftis; Marilyn Huckans; Benjamin J Morasco
Journal:  Neurobiol Dis       Date:  2009-11-26       Impact factor: 5.996

3.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

Authors:  Fabrice Carrat; Firouzé Bani-Sadr; Stanislas Pol; Eric Rosenthal; Françoise Lunel-Fabiani; Asmae Benzekri; Patrice Morand; Cécile Goujard; Gilles Pialoux; Lionel Piroth; Dominique Salmon-Céron; Claude Degott; Patrice Cacoub; Christian Perronne
Journal:  JAMA       Date:  2004-12-15       Impact factor: 56.272

4.  Pain syndromes and etiologies in ambulatory AIDS patients.

Authors:  D J Hewitt; M McDonald; R K Portenoy; B Rosenfeld; S Passik; W Breitbart
Journal:  Pain       Date:  1997-04       Impact factor: 6.961

5.  Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients.

Authors:  A Barkhuizen; H R Rosen; S Wolf; K Flora; K Benner; R M Bennett
Journal:  Am J Gastroenterol       Date:  1999-05       Impact factor: 10.864

6.  Panic disorder and pain in a national sample of persons living with HIV.

Authors:  Jennie C I Tsao; Aram Dobalian; Bruce D Naliboff
Journal:  Pain       Date:  2004-05       Impact factor: 6.961

Review 7.  Fibromyalgia, hepatitis C infection, and the cytokine connection.

Authors:  Mollie E Thompson; André Barkhuizen
Journal:  Curr Pain Headache Rep       Date:  2003-10

8.  Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha.

Authors:  Jennifer M Loftis; Marilyn Huckans; Samantha Ruimy; David J Hinrichs; Peter Hauser
Journal:  Neurosci Lett       Date:  2007-11-06       Impact factor: 3.046

9.  Depression and drug use impact health status among marginally housed HIV-infected individuals.

Authors:  Elise D Riley; Albert W Wu; Sharon Perry; Richard A Clark; Andrew R Moss; Johanna Crane; David R Bangsberg
Journal:  AIDS Patient Care STDS       Date:  2003-08       Impact factor: 5.078

10.  Illness burden mediates the relationship between pain and illicit drug use in persons living with HIV.

Authors:  Jennie C I Tsao; Aram Dobalian; Judith A Stein
Journal:  Pain       Date:  2005-11-16       Impact factor: 7.926

View more
  10 in total

1.  Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.

Authors:  Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow
Journal:  AIDS       Date:  2016-01       Impact factor: 4.177

2.  Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders.

Authors:  Judith I Tsui; Marlene C Lira; Debbie M Cheng; Michael R Winter; Daniel P Alford; Jane M Liebschutz; Jianren Mao; Robert R Edwards; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2015-05-22       Impact factor: 4.492

3.  Biopsychosocial factors associated with pain in veterans with the hepatitis C virus.

Authors:  Benjamin J Morasco; Travis I Lovejoy; Dennis C Turk; Aysha Crain; Peter Hauser; Steven K Dobscha
Journal:  J Behav Med       Date:  2013-12-14

4.  Pain Symptoms Associated with Opioid Use among Vulnerable Persons with HIV: An exploratory study with implications for palliative care and opioid abuse prevention.

Authors:  Amy R Knowlton; Trang Q Nguyen; Allysha C Robinson; Paul T Harrell; Mary M Mitchell
Journal:  J Palliat Care       Date:  2015       Impact factor: 2.250

5.  Rheumatic diseases in HIV-infected patients in the post-antiretroviral therapy era: a tertiary care center experience.

Authors:  Konstantinos Parperis; Yasir Abdulqader; Robert Myers; Bikash Bhattarai; Muhsen Al-Ani
Journal:  Clin Rheumatol       Date:  2018-04-04       Impact factor: 2.980

Review 6.  Depression, fatigue and neurocognitive deficits in chronic hepatitis C.

Authors:  Sern Wei Yeoh; Alex C N Holmes; Michael M Saling; Ian P Everall; Amanda J Nicoll
Journal:  Hepatol Int       Date:  2018-06-21       Impact factor: 6.047

7.  Continued Substance Use Among People Living With HIV-Hepatitis-C Co-Infection and Receiving Antiretroviral Therapy.

Authors:  Seth C Kalichman; Christopher Washington; Christopher Kegler; Tamar Grebler; Moira O Kalichman; Chauncey Cherry; Lisa Eaton
Journal:  Subst Use Misuse       Date:  2015-11-19       Impact factor: 2.164

8.  Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection.

Authors:  Alexis Ogdie; Wyki Gina Pang; Kimberly A Forde; Bhangle D Samir; Lakeisha Mulugeta; Kyong-Mi Chang; David E Kaplan; Valerianna K Amorosa; Jay R Kostman; Rajender K Reddy; Ralph H Schumacher; Vincent Lo Re
Journal:  BMC Musculoskelet Disord       Date:  2015-04-19       Impact factor: 2.362

9.  Prevalence and Medication Treatment of Opioid Use Disorder Among Primary Care Patients with Hepatitis C and HIV.

Authors:  Judith I Tsui; Mary A Akosile; Gwen T Lapham; Denise M Boudreau; Eric A Johnson; Jennifer F Bobb; Ingrid A Binswanger; Bobbi Jo H Yarborough; Joseph E Glass; Rebecca C Rossom; Mark T Murphy; Chinazo O Cunningham; Julia H Arnsten; Manu Thakral; Andrew J Saxon; Joseph O Merrill; Jeffrey H Samet; Gavin B Bart; Cynthia I Campbell; Amy M Loree; Angela Silva; Angela L Stotts; Brian Ahmedani; Jordan M Braciszewski; Rulin C Hechter; Thomas F Northrup; Viviana E Horigian; Katharine A Bradley
Journal:  J Gen Intern Med       Date:  2021-02-10       Impact factor: 5.128

10.  Psychosocial factors associated with persistent pain in people with HIV: a systematic review with meta-analysis.

Authors:  Whitney Scott; Chinar Arkuter; Kitty Kioskli; Harriet Kemp; Lance M McCracken; Andrew S C Rice; Amanda C de C Williams
Journal:  Pain       Date:  2018-12       Impact factor: 6.961

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.